The rate of porphyrin biosynthesis in mammals is controlled by the activity of the pyridoxal 5-phosphate-dependent enzyme 5-aminolevulinate synthase (EC 2.3.1.37). Based on the postulate that turnover in this enzyme is controlled by conformational dynamics associated with a highly conserved active site loop, we constructed a variant library by targeting imperfectly conserved noncatalytic loop residues and examined the effects on product and porphyrin production. Functional loop variants of the enzyme were isolated via genetic complementation in Escherichia coli strain HU227. Colony porphyrin fluorescence varied widely when bacterial cells harboring the loop variants were grown on inductive media; this facilitated identification of clones encoding unusually active enzyme variants. Nine loop variants leading to high in vivo porphyrin production were purified and characterized kinetically. Steady state catalytic efficiencies for the two substrates were increased by up to 100-fold. Presteady state single turnover reaction data indicated that the second step of quinonoid intermediate decay, previously assigned as reaction rate-limiting, was specifically accelerated such that in three of the variants this step was no longer kinetically significant. Overall, our data support the postulate that the active site loop controls the rate of product and porphyrin production in vivo and suggest the possibility of an as yet undiscovered means of allosteric regulation.
Aminolevulinate (ALA)2 is the universal building block of tetrapyrolle biosynthesis (1). In nonplant eukaryotes and the ␣-subclass of purple bacteria, the production of ALA is catalyzed by the pyridoxal 5Ј-phosphate (PLP)-dependent enzyme 5-aminolevulinate synthase (ALAS) (EC 2.3.1.37), in a reaction involving the Claisen-like condensation of succinyl-coenzyme-A and glycine to yield CoA, carbon dioxide, and ALA (2). ALAS catalyzes the first committed step of tetrapyrrole biosynthesis in these organisms, which is also the rate-determining step of the pathway. Consequently, overexpression of ALAS in prokaryotic and eukaryotic cells results in accumulation of the photosensitizing heme precursor protoporphyrin IX (3). This property could potentially lead to novel applications of ALAS or ALAS variants in photodynamic therapy of tumors and other dysplasias (4).ALAS is classified as a fold-type I PLP-dependent enzyme and, like the evolutionarily related L-amino acid transaminases (5), functions as a homodimer wherein a PLP cofactor is bound at each of the two active sites, which are recessed in clefts at the subunit interface (6, 7). X-ray crystal structures of ALAS from Rhodobacter capsulatus and the closely related enzyme 8-amino-7-oxononanoate synthase from Escherichia coli reveal an induced fit type mechanism wherein binding of substrates and product, respectively, trigger closure of an extended loop over the active site (6, 8) (Fig. 1). The inferred conformational dynamics of this loop are of interest because kinetic and crystallographic studies support the hypothes...